Argos Therapeutics (ARGS) Misses Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts ARGS Hot Sheet
Join SI Premium – FREE
Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.83), $0.10 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $670 thousand.
For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
- Williams-Sonoma (WSM) Tops Q2 EPS by 4c
- LightInTheBox Holding (LITB) Reports Q2 EPS of $0.01
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
